Metastatic castration-resistant prostate cancer
Emily MenendezCRPC | May 7, 2024
Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently.
Read More
Zachary BessetteCRPC | May 3, 2024
Results from the third interim analysis of the DAROL study indicate real-world effectiveness in patients with nmCRPC.
Katy MarshallCRPC | April 23, 2024
The study sought to determine the outcomes and prevalence related to somatic or germline HRR alterations.
Katy MarshallCRPC | April 10, 2024
The data were sourced from a deidentified US-based metastatic prostate cancer clinicogenomic database.
Daniel Spratt, MDLocalized | April 5, 2024
Dr. Spratt reviews the safety and efficacy of relugolix plus RT in patients with localized or advanced prostate cancer.
Katy MarshallCRPC | April 1, 2024
OS was compared using Cox proportional hazards models with IPTW adjusted for baseline characteristics.
Katy MarshallProstate Cancer Diagnostics | March 25, 2024
Cohort 4 of the trial is the final dose-escalation phase and will be followed by a dose-expansion phase.
Daniel J. George, MD, FASCOCRPC | March 6, 2024
Dr. George delves into research for HRR mutation testing in mCRPC, including strategies for earlier testing after diagnosis.
Katy MarshallCRPC | March 1, 2024
The open-label VISON study randomly assigned patients to receive either 177Lu-PSMA-617 plus SoC or SoC alone.
Katy MarshallRLT | February 14, 2024
A total of 488 patients received an average of 2 cycles of 225Ac-PSMA RLT between January 2016 and May 2023.
Katy MarshallCRPC | February 13, 2024
Patients had previously received an androgen blockade with bicalutamide and an alternative AAT with flutamide.
Emily MenendezASCO GU Symposium 2024 | January 27, 2024
The study analyzed VISION-eligible patients with mCRPC who were classified as TheraP-eligible or ineligible.
Emily MenendezASCO GU Symposium 2024 | January 27, 2024
The study is the first large-scale report of patients in the United States treated with 177Lu-PSMA-617.
Pedro Barata, MDASCO GU Symposium 2024 | January 30, 2024
Drs. Barata and Wallis discuss the interaction of age and benefit of treatment intensification in advanced prostate cancer.
Brad McGregor, MDASCO GU Symposium 2024 | January 30, 2024
Drs. McGregor and Wallis highlight CONTACT-2, the first study of an ICI-based regimen to show improvement in rPFS in PC.
Emily MenendezASCO GU Symposium 2024 | January 26, 2024
HRQoL was maintained in the niraparib plus AAP arm, and patients experienced minimal side effect bother from treatment.
Katy MarshallASCO GU Symposium 2024 | January 26, 2024
The enzalutamide group experienced a significant deterioration in mean fatigue changes when compared with the AA group.
Christopher Wallis, MD, PhD, FRCSCASCO GU Symposium 2024 | January 25, 2024
Dr. Maha Hussain presented results of the BRCAAway trial in patients with mCRPC who have HRR mutations.
Zachary BessetteASCO GU Symposium 2024 | January 24, 2024
Cabozantinib plus atezolizumab improves rPFS versus second NHT in patients who had progressed on a prior NHT and have mCRPC.
Emily MenendezCRPC | January 10, 2024
There has been renewed interest in the platinum-based treatment of metastatic castration-resistant prostate cancer.